The full report suite on the U.S. market for dialysis includes hemodialysis and peritoneal dialysis machines, dialysis catheters, dialyzers, dialyzer reprocessing machines, hemodialysis bloodline and tubing sets, AV fistula needles, AV access grafts, declotting devices, introducer sheaths and guidewires and water treatment systems. The dialysis patient population has been increasing since 2013 and is projected to continue increasing over the forecast period. Notable trends include shifts between hemodialysis patients and peritoneal dialysis patients as well as the rate of transition from in-center treatment options to personal, home treatment.
Arteriovenous (AV) is the most common method of access for hemodialysis treatment in patients that are suffering from end-stage renal disease (ESRD). AV access can be achieved via either AV fistula or AV graft. The fistula can be made in an extremity, typically in the forearm, where an artery and vein are surgically connected. This connection matures and strengthens over a period of four to six weeks. Native fistulae offer the best patency and durability, in addition to limiting complications such as post-dialysis bleeding and infection. A native fistula is the preferred access technique.